Western Blot: Lamin A + C Antibody [NB100-56649] - Analysis of human Lamin A + C in 15 ug of HeLa cell lysate using NB100-56649 at 1:1000.
Immunocytochemistry/ Immunofluorescence: Lamin A + C Antibody [NB100-56649] - Lamin A/C antibody was tested in A431 cells at 1:100 against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against ...read more
Flow (Intracellular): Lamin A + C Antibody [NB100-56649] - Intracellular staining of HeLa cells (1 x 10^6 cells/mL) with Lamin A+C antibody (orange) stained at 1:1000. Detected with a GtxRb DyLight 488 secondary. Shown ...read more
Lamin A and lamin C are alternative splicing products of the lamin A/C gene that is responsible for autosomal dominant Emery-Dreifuss muscular dystrophy (AD-EDMD) (1). Aberrant expression patterns of nuclear lamins have been described in various types of cancer depending on the subtype of cancer, its aggressiveness, proliferative capacity and degree of differentiation. In general, the expression of A-type lamins (lamins A and C) has been correlated with a non-proliferating, differentiated state of cells and tissues. Lamins A and C, the products of the LMNA gene, are nuclear intermediate filament proteins and are the major structural components of the lamina network that underlies and supports the nuclear envelope (2).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Lamin A + C Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.